Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
Affiliation
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.Issue Date
1989-07
Metadata
Show full item recordAbstract
Forty-two patients with small cell lung cancer were treated with a combination of carboplatin, ifosfamide and etoposide. Vincristine was given on day 14 of each course, the courses being repeated every 28 days for a maximum of six. Thoracic radiotherapy was given 4 weeks after the last course of chemotherapy but no prophylactic cranial radiotherapy was administered. Thirty patients had clinically limited state disease, the remaining patients having contralateral neck lymphadenopathy and/or pleural effusions. Elevated enzyme levels (alkaline phosphatase, LDH, ALT, GGT) were noted in 69% of patients. Twenty-four patients (57%) achieved a complete response (CR) when assessed one month after the end of treatment. A further 21% of patients had a partial response (PR). Median duration of CR was 14 months and of PR 8 months. Cerebral metastases were the sole site of relapse in 13% of the CR patients. Myelosuppression was severe with a median nadir of neutropenia of 0.2 x 10(9) cells 1-1. However, 74% of the patient group received all six courses of chemotherapy and only 16 courses (7%) were delayed because of toxicity. There were three deaths associated with treatment-related neutropenia. The median survival of the total group was 14 months, with an actuarial 2 year survival of 37% and a minimum follow-up of 18 months. [A recent analysis, March 1989, demonstrated a 33%, 2 year actual survival.]Citation
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus. 1989, 60 (1):98-101 Br J CancerJournal
British Journal of CancerPubMed ID
2553090Type
ArticleLanguage
enISSN
0007-0920Collections
Related articles
- Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
- Authors: Prendiville J, Radford J, Thatcher N, Steward W, Ranson M, Burt P, Stout R
- Issue date: 1991 Aug
- Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation.
- Authors: Prendiville J, Lorigan P, Hicks F, Leahy B, Stout R, Burt P, Thatcher N
- Issue date: 1994
- Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
- Authors: Smith IE, Perren TJ, Ashley SA, Woodiwiss J, Forgeson GV, Yarnold JR, Ford HT
- Issue date: 1990 May
- Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
- Authors: Bishop JF, Kefford R, Raghavan D, Zalcberg J, Stuart-Harris R, Ball D, Olver IN, Friedlander M, Bull C, Yuen K
- Issue date: 1990
- Carboplatin in small cell lung cancer.
- Authors: Thatcher N, Lind M
- Issue date: 1990 Feb